This finding implies that patients with longer overall survival periods are positively correlated with anti-tumor scores for certain signature genes with high expression (CCKBR, KCNJ11, ITGA10, and IGFBP1) and other signature genes with low expression (NMU, MMP13 and CEACAM5). This evidence concerns the gene NMU and neoplasm.